Mutant Beta-Glucuronidase Enzymes for Rapid Drug Analysis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current commercially available β-glucuronidase enzyme preparations for drug testing are inefficient, requiring several hours to analyze a sample due to low enzyme activity and contamination from other proteins, leading to prolonged evaluation times.
Innovation Solution
Development of mutant β-glucuronidase enzymes with enhanced enzymatic activity and thermal stability, achieved through specific amino acid substitutions such as G559S, G559T, and the addition of a cysteine residue at the C-terminal end, allowing for rapid analysis of drug samples within 30 minutes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If commercially available BGUS enzyme preparations are used, then drug detection function is provided, but analysis time is prolonged (several hours to two days)
Solution Approach 1:
The patent applies parameter changes by modifying the amino acid sequence of the BGUS enzyme through site-directed mutagenesis. Specific amino acid substitutions (e.g., G559S, G559T, G559H, G559N) were introduced to enhance enzymatic activity, reducing analysis time from several hours to 30 minutes or less while maintaining detection accuracy.
Solution Approach 2:
The patent creates a recombinant copy of the mutated BGUS enzyme gene and expresses it in E. coli bacteria. This allows production of large quantities of highly active enzyme without relying on crude extracts from natural sources, thereby achieving rapid analysis while ensuring enzyme purity and consistency.
2Power
If crude extract forms of BGUS enzyme are used, then enzyme activity is provided, but contamination from other proteins occurs which interferes with activity
Solution Approach 1:
The patent extracts only the essential BGUS enzyme component by using recombinant expression systems. The mutated BGUS gene is cloned into expression vectors and expressed in E. coli, allowing isolation of pure enzyme without contaminating proteins found in crude extracts from snails or abalone, thereby ensuring both high activity and reliability.
Solution Approach 2:
The patent utilizes the E. coli bacterial system's natural protein expression machinery to produce the mutated BGUS enzyme. The bacteria serve as living factories that self-assemble the enzyme according to the provided genetic instructions, yielding high-purity product without requiring complex purification from animal tissues.
3Stability of the object's composition
If wild type BGUS enzyme is used, then natural enzyme function is maintained, but thermal stability is insufficient
Solution Approach 1:
The patent applies parameter changes by systematically modifying amino acid residues in the BGUS enzyme sequence. Through rational design and site-directed mutagenesis, specific substitutions were made to enhance both thermal stability and catalytic activity, transforming the enzyme's physical and chemical parameters to overcome limitations of the wild type.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The mutant enzymes provide significantly increased enzymatic activity and stability, enabling rapid and accurate analysis of drug samples, reducing evaluation time and minimizing contamination from other proteins.
Implementation Method 1
The β-glucuronidase (BGUS) enzyme catalyzes the hydrolysis of a wide variety of β-glucuronides
Implementation Method 2
the BGUS enzyme catalyzes the hydrolysis of a wide variety of β-glucuronides
Data Source
AI summary
Mutated β-glucuronidase enzymes with enhanced enzymatic activity and thermostability as compared to wild type enzyme are provided. The enzymes of the invention advantageously allow for accurate analysis of bodily samples for the presence of drugs in 30 minutes or less, as compared to the several hours needed using prior enzyme preparations. Methods of using the mutated enzymes for hydrolysis of glucuronide substrates, including opiates and benzodiazepines, are also provided.